{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:47:12Z","timestamp":1778539632604,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"DOI":"10.7759\/cureus.34800","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:05:08Z","timestamp":1675951508000},"source":"Crossref","is-referenced-by-count":4,"title":["Generalized Drug Eruption Secondary to Ticagrelor: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Raziye E","family":"Akdogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Varon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnara","family":"Muradova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-019-1030-6","article-title":"Increase in ticagrelor use over time is associated with lower rates of ischemic stroke following myocardial infarction","volume":"19","author":"Henriksson R","year":"2019","unstructured":"Henriksson R, Ulvenstam A, S\u00f6derstr\u00f6m L, Mooe T. Increase in ticagrelor use over time is associated with lower rates of ischemic stroke following myocardial infarction. BMC Cardiovasc Disord. 2019, 19:51. 10.1186\/s12872-019-1030-6","journal-title":"BMC Cardiovasc Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.6447","article-title":"Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"180","author":"Turgeon RD","year":"2020","unstructured":"Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, Graham MM. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020, 180:420-8. 10.1001\/jamainternmed.2019.6447","journal-title":"JAMA Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.04.011","article-title":"First report of hypersensitivity to ticagrelor","volume":"30","author":"Quinn KL","year":"2014","unstructured":"Quinn KL, Connelly KA. First report of hypersensitivity to ticagrelor. Can J Cardiol. 2014, 30:957.e3-4. 10.1016\/j.cjca.2014.04.011","journal-title":"Can J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2017.7.1.51","article-title":"Hypersensitivity to ticagrelor and low response to clopidogrel: a case report","volume":"7","author":"Dai J","year":"2017","unstructured":"Dai J, Lyu S, Ge C. Hypersensitivity to ticagrelor and low response to clopidogrel: a case report. Asia Pac Allergy. 2017, 7:51-3. 10.5415\/apallergy.2017.7.1.51","journal-title":"Asia Pac Allergy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.04.264","article-title":"Ticagrelor-induced acute generalized exanthematous pustulosis","volume":"191","author":"Maybrook RJ","year":"2015","unstructured":"Maybrook RJ, Fischer R, Deibert B, et al.. Ticagrelor-induced acute generalized exanthematous pustulosis. Int J Cardiol. 2015, 191:11-2. 10.1016\/j.ijcard.2015.04.264","journal-title":"Int J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2019-136426","article-title":"Ticagrelor induced neutrophilic eccrine hidradenitis: a unique adverse effect of a new antiplatelet drug","volume":"95","author":"Bishnoi A","year":"2019","unstructured":"Bishnoi A, Daroach M, Aggarwal D, Radotra BD, Panda P, Parsad D. Ticagrelor induced neutrophilic eccrine hidradenitis: a unique adverse effect of a new antiplatelet drug. Postgrad Med J. 2019, 95:279-80. 10.1136\/postgradmedj-2019-136426","journal-title":"Postgrad Med J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13890","article-title":"Suspected ticagrelor-induced bullous fixed drug eruption","volume":"13","author":"Kawall T","year":"2021","unstructured":"Kawall T, Seecheran R, Seecheran V, Persad S, Seecheran NA. Suspected ticagrelor-induced bullous fixed drug eruption. Cureus. 2021, 13:e13890. 10.7759\/cureus.13890","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12928-016-0398-9","article-title":"Ticagrelor-induced Sweet syndrome: an unusual dermatologic complication after percutaneous coronary intervention","volume":"32","author":"Ikram S","year":"2017","unstructured":"Ikram S, Veerappan Kandasamy V. Ticagrelor-induced Sweet syndrome: an unusual dermatologic complication after percutaneous coronary intervention. Cardiovasc Interv Ther. 2017, 32:244-6. 10.1007\/s12928-016-0398-9","journal-title":"Cardiovasc Interv Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin L","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al.. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009, 361:1045-57. 10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.11.002","article-title":"Management of clopidogrel hypersensitivity without drug interruption","volume":"107","author":"Campbell KL","year":"2011","unstructured":"Campbell KL, Cohn JR, Fischman DL, Walinsky P, Mallya R, Jaffrani W, Savage MP. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol. 2011, 107:812-6. 10.1016\/j.amjcard.2010.11.002","journal-title":"Am J Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/137366-generalized-drug-eruption-secondary-to-ticagrelor-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:12Z","timestamp":1707508752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/137366-generalized-drug-eruption-secondary-to-ticagrelor-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.34800","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}